Research programme: plasma kallikrein inhibitors - Attune Pharmaceuticals

Drug Profile

Research programme: plasma kallikrein inhibitors - Attune Pharmaceuticals

Alternative Names: ATN-035; ATN-249

Latest Information Update: 06 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Attune Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Plasma-kallikrein-inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Hereditary angioedema

Most Recent Events

  • 23 May 2017 Pharmacokinetic and safety data from preclinical trials in Hereditary angioedema released by Attune Pharmaceuticals
  • 06 Mar 2017 Attune Pharmaceuticals plans phase I pharmacokinetic studies for Hereditary angioedema (In volunteers) in Australia (ACTRN12618000430235)
  • 06 Mar 2017 Pharmacodynamics, pharmacokinetics and adverse events data from preclinical studies in Hereditary angioedema presented at the 2017 American Academy of Allergy, Asthma & Immunology Annual Meeting (AAAAI-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top